Literature DB >> 15181965

Clinical experience in the management of neovascular glaucoma.

Tung-Mei Kuang1, Catherine Jui-Ling Liu, Ching-Kuang Chou, Wen-Ming Hsu.   

Abstract

BACKGROUND: Neovascular glaucoma (NVG) is a devastating ocular disease with poor prognosis. The ideal surgical procedure has yet to be determined. In this study, the clinical course and visual outcome of NVG and their fellow eyes were investigated and the most appropriate management was also evaluated.
METHODS: The study was conducted retrospectively consisting of NVG in-patients of Taipei Veterans General Hospital who were under the care of the same glaucoma specialist between January, 1998 and September, 2000. All patients had a minimal follow-up period of 6 months.
RESULTS: The total number of patients enrolled was 35 (number of eyes enrolled was 35) with mean age of 66.4 +/- 12.3 years. The underlying cause was diabetes mellitus in 29 patients and central retinal vein occlusion in 6 patients. Twelve (34.3%) eyes had initial intraocular pressure (IOP) of over 60 mmHg. Only 1 (2.9%) eye had initial visual acuity better than 6/60. Four lesion eyes were able to receive panretinal photocoagulation whereas 31 eyes received panretinal cryotherapy. For IOP reducing procedures, 15 eyes received trabeculectomy, and 16 received Diode trans-scleral cyclophotocoagulation (TSCP). At the final visit, 20 eyes (trabeculectomy group: 11 and Diode TSCP group: 9) were able to maintain an IOP < or = 21 mmHg. Of these eyes, 15 (trabeculectomy group: 8 and Diode TSCP group: 7) were able to maintain or improve their vision. Of the remaining 4 eyes, 2 had cyclocryotherapy and 2 had trabeculectomy followed by Diode TSCP. IOP were controlled in these 4 eyes but none were able to maintain stable vision. Among the 34 fellow eyes with stable IOP, 32 were able to maintain stable vision.
CONCLUSIONS: Trabeculectomy and Diode TSCP provided no statistically significant difference in IOP control (p = 0.32) and visual outcome (p = 0.59) in our patient group. More randomized, prospective trials are needed to define the most effective treatment for NVG.

Entities:  

Mesh:

Year:  2004        PMID: 15181965

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  6 in total

1.  [Neovascular glaucoma: aetiology, pathogenesis and treatment].

Authors:  K U Löffler
Journal:  Ophthalmologe       Date:  2006-12       Impact factor: 1.059

2.  Surgical results of pars plana vitrectomy combined with pars plana lensectomy with anterior capsule preservation, endophotocoagulation, and silicon oil tamponade for neovascular glaucoma.

Authors:  Nozomi Kinoshita; Ayumi Ota; Fumihiko Toyoda; Hiroko Yamagami; Akihiro Kakehashi
Journal:  Clin Ophthalmol       Date:  2011-12-16

3.  Non-housekeeping genes expressed in human trabecular meshwork cell cultures.

Authors:  Seyed Hassan Paylakhi; Shahin Yazdani; Craig April; Jian-Bing Fan; Hamidreza Moazzeni; Mostafa Ronaghi; Elahe Elahi
Journal:  Mol Vis       Date:  2012-01-28       Impact factor: 2.367

4.  Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications.

Authors:  Lan Liu; Yongfeng Xu; Zhu Huang; Xiaoyu Wang
Journal:  BMC Ophthalmol       Date:  2016-05-26       Impact factor: 2.209

Review 5.  Bevacizumab in Glaucoma: Where do We Stand?

Authors:  Anjani Khanna
Journal:  J Curr Glaucoma Pract       Date:  2012-08-16

6.  Efficacy and Safety of Combined Surgeries including Intraocular Direct Cyclophotocoagulation with a 532 nm Laser to Treat Advanced Neovascular Glaucoma.

Authors:  Xiaomin Chen; Tian Zheng; Wen Zeng; Xia Fu; Shun Wang; Weijuan Zeng; Min Ke
Journal:  J Ophthalmol       Date:  2021-07-07       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.